Connect your AI

Bioventus BVS Finance Lease Liabilities

Finance Lease Liabilities at other companies

MedtronicMDT

$54M+3.8%

ArtivionAORT

$3.05M+1.0%

Globus MedicalGMED

$398K+54.9%

AxogenAXGN

$27K-3.6%

3D SystemsDDD

$9.2M-10.7%

Other financials

Income statement

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bioventus's finance lease liabilities?: Bioventus (BVS) reported finance lease liabilities of $8.48M in Q1 2026.
How has Bioventus's finance lease liabilities changed year-over-year?: Bioventus's finance lease liabilities decreased by 9.9% year-over-year, from $9.41M to $8.48M.
What is the long-term trend for Bioventus's finance lease liabilities?: Over 3 years (2022 to 2025), Bioventus's finance lease liabilities has grown at a 386.1% compound annual growth rate (CAGR), from $76K to $8.73M.
What does finance lease liabilities mean?: Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.